Supplementation with Herbal Extracts to Promote Behavioral and Neuroprotective Effects in Experimental Models of Parkinson's Disease: A Systematic Review

Phytotherapy Research

Volumn 31, Issue 7, 2017, Pages 959-970

  da Costa, Ianara Mendonça ^a   Cavalcanti, José Rodolfo Lopes de Paiva ^a   de Queiroz, Dinalva Brito ^b   de Azevedo, Eduardo Pereira ^b   do Rêgo, Amália Cinthia Meneses ^b   Araújo Filho, Irami ^b   Parente, Paulo ^c   Botelho, Marco Antônio ^b   Guzen, Fausto Pierdoná ^a,b  

^a DEPARTAMENTO DE FÍSICA   (Brazil)

^b POTIGUAR UNIVERSITY   (Brazil)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

antioxidant activity; dopamine; medicinal plants; Parkinson's disease

Indexed keywords

AMANTADINE; BAICALEIN; BIGNONIA SUAVEOLENS EXTRACT; COMBRETUM LEPROSUM EXTRACT; CURCUMIN; DOPAMINE; DOPAMINE 2 RECEPTOR; ECHINACOSIDE; GINSENG EXTRACT; LEVODOPA; MADECASSOSIDE; MYRACRODRUON URUNDEUVA EXTRACT; NATURAL PRODUCT; PELARGONIN; PLANT EXTRACT; SAFFLOWER EXTRACT; SILYMARIN; SINECATECHINS; TINOSPORA CORDIFOLIA EXTRACT; TRIPTOLIDE; UNCLASSIFIED DRUG; VELVET BEAN EXTRACT; WITHANIA SOMNIFERA EXTRACT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BEHAVIOR; BIGNONIA SUAVEOLENS; BIGNONIACEAE; COMBRETUM; COMBRETUM LEPROSUM; DOPAMINE METABOLISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEDICINAL PLANT; MYRACRODRUON URUNDEUVA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SINGLE DRUG DOSE; SUPPLEMENTATION; SYSTEMATIC REVIEW; VELVET BEAN; ANIMAL; APOPTOSIS; BIOSYNTHESIS; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; PHYTOTHERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOPAMINERGIC NEURONS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 85019585095     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5813     Document Type: Review

References (77)

1. Antunes MS, Goes ATR, Boeira SP, Prigol M, Jesse CR. 2014. Protective effect of hesperidin in a model of Parkinson's disease induced by 6-hydroxydopamine in aged mice. Nutrition 30: 1415–1422.
2. Anandhan A, Tamilselvam K, Radhiga T, Rad S, Essa MM, Manivasagam T. 2012. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. Brain Res 1433: 104–113.
3. Arulkumar S, Sabesan M. 2012. The behavioral performance tests of Mucuna pruriens gold nanoparticles in the 1-methyl4-phenyl-1,2,3,6-tetrahydropiridina treated mouse model of Parkinsonism. Asian Pac J Trop Dis 2: 499–502.
4. Baluchnejadmojarad T, Roghani M, Mafakheri M. 2010. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 23: 206–210.
5. Bobby T, Flint BM. 2007. Parkinson's disease. Hum Mol Genet 16: 183–194.
6. Bové J, Prou D, Perier C, Przedborski S. 2005. Toxin-induced models of Parkinson's disease. NeuroRx 2: 484–494.
7. Calou I, Bandeira MA, Galvão WA, et al. 2014. Neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as evaluated by a Parkinson's disease model in rats. Park Dis 2014: 1–11.
8. Caruana M, Vasallo N. 2015. Tea Polyphenols in Parkinson's Disease. Adv Exp Med Biol 863: 117–137. https://doi.org/10.1007/978-3-319-18365-7_6.
9. Chan WS, Durairajan SS, Lu JH, et al. 2009. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem Int 55: 414–442.
10. Chaturvedi RK, Shukla S, Seth K, et al. 2007. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 22: 421–434.
11. Checkoway H, Powers K, Smith-weller T, Franklin GM, Longstreth WT Jr, Swanson PD. 2002. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155: 732–738.
12. Chen H, Jing FC, Li CH, Tu PF, Zheng QS, Wang ZH. 2007. Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats. J Ethnopharmacol 114: 285–289.
13. Cheng Y, He G, Mu X, et al. 2008. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, bochemical and immunohistochemical profile. Neurosci Lett 441: 16–20.
14. Choi HS, Park MS, Km SH, Hwang BY, Lee CK, Lee MK. 2010. Neuroprotective effects of herbal etanol extracts from Gynostemma pentaphyllum in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Molecules 15: 2814–2824.
15. Doshay LJ. 1956. The therapy of Parkinson's disease. Med Clin North Am 40: 1401–1415.
16. Eghbaliferiz S, Iranshahi M. 2016. Prooxidant activity of polyphenols, flavonoids, anthocyanins and carotenoids: updated review of mechanisms and catalyzing metals. Phytother Res 30: 1379–1391.
17. Fahn S. 2004. Levodopa and the progression of Parkinson's disease. N Engl J Med 351: 2498–2508.
18. Filichia E, Hoffer B, Qi X, Luo Y. 2016. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP. Sci Rep 6: 32656. https://doi.org/10.1038/srep32656.
19. Gao JP, Sun S, Li WW, Cai DF. 2008. Triptolide protects against 1-methyl-4-phenylpyridinium-induced dopaminergic neurotoxicity in rats: implication for immunossupressive therapy in Parkinson's disease. Neurosci Bull 24: 133–142.
20. Geed M, Garabadu D, Ahmad A, Krishmamurthy S. 2014. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats. Pharmacol Biochem Behav 117: 92–103.
21. Geng X, Tian X, Tu P, Pu X. 2007. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease. Eur J Pharmacol 564: 66–74.
22. Guo S, Yan J, Yang T, Xianquiang Y, Erwan B, Baolu Z. 2007. Protective effect of green tea polyphenols in the 6-OHDA rat modelo f Parkinson's disease through inhibition of ROS–NO pathway. Biol Psychiatry 62: 1353–1362.
23. Goszcz K, Duthie GG, Stewart D, Leslie SJ, Megson IL. 2017. Bioactive polyphenols and cardiovascular disease: chemical antagonists, pharmacological agents or xenobiotics that drive an adaptive response? Br J Pharmacol. https://doi.org/10.1111/bph.13708.
24. Guo S, Bezard E, Zhao B. 2005. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS–NO pathway. Free Radic Biol Med 39: 682–695.
25. Gupta VK, Sharma SK. 2006. Plants as natural antioxidants. Nat Prod Rad 5: 326–334.
26. Haddadi R, Nayebi AM, Brooshghalan SE. 2013. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-Parkinsonian rats. Neurosci Lett 555: 106–111.
27. Han B, Hu J, Shen J, Gao Y, Hu Y, Wang T. 2013. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats. Eur J Pharmacol 714: 83–88.
28. Islam MT, da Silva CB, de Alencar MV, Paz MF, Almeida FR, Melo-Cavalcante AA. 2016. Diterpenes: advances in neurobiological drug research. Phytother Res 30: 915–928. https://doi.org/10.1002/ptr.5609.
29. Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM. 2016. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res 30: 691–700.
30. Kaakkola S, Teravainen H. 1990. Animal models of Parkinsonism. Pharmacol Toxicol 67: 95–100.
31. Khuwaja G, Kham MM, Ishrat T, et al. 2011. Neuroprotective effects of curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: behavioral, neurochemical and immunohistochemical studies. Brain Res 136: 254–263.
32. Kim BW, Koppula S, Park SY, et al. 2015. Attenuation of neurinflamatory responses and behavioral déficits by Ligusticum officinale (Makino) kitag in stimulated micróglia and MPTP-induced mouse modelo of Parkinson's disease. J Ethnopharmacol 164: 388–397.
33. Kim TH, Cho KH, Jung WS, Lee MS. 2012. Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trials. PLoS One 7: e35695.
34. Kosaraju J, Chinni S, Roy PD, Kannan E, Antony AS, Kumar MNS. 2014. Neuroprotective effect of Tinospora cordifolia etanol extract on 6-hydroxy dopamine induced Parkinsonism. Indian J Pharm 46: 176–180.
35. Li G. 1995. Clinical analysis of Parkinson's disease treated by integration of traditional Chinese and western medicine. J Tradit Chin Med 15: 163–169.
36. Li XZ, Zhang SN, Liu SM, Lu F. 2013. Recent advances in herbal medicines treating Parkinson's disease. Fitoterapia 84: 273–285.
37. Lin BW, Gong CC, Song HF, Cui YY. 2016. Effects of anthocyanins on the prevention and treatment of cancer. Br J Pharmacol. https://doi.org/10.1111/bph.13627.
38. Liu SM, Li XZ, Huo Y, Lu F. 2012. Protective effect of Acanthopanax senticosus harms on dopaminergic neurons in Parkinson's disease mice. Phytomedicine 19: 631–638.
39. Lu X, Kim-Han JS, Harmon S, Sakiyama-Elbert SE, Lo'malley K. 2014. The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol Neurodegener 9: 1–11. https://doi.org/10.1186/1750-1326-9-17.
40. Mu X, He GR, Yuan X, Li XX, Du GH. 2011. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. Pharmacol Biochem Behav 98: 286–291.
41. Moraes LS, Rohor BZ, Areal LB, et al. 2016. Medicinal plant Combretum leprosum mart amelioratesmotor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP. J Ethnopharmacol 185: 68–76.
42. Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. 2000. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 176: 124–127.
43. Perese DA, Ulman J, Viola J, Bankiewicz KS. 1989. A 6 hydroxydopamine-induced selective Parkinsonian rat model. Brain Res 494: 285–293.
44. Peluso I, Serafini M. 2016. Antioxidants from black and green tea: from dietary modulation of oxidative stress to pharmacological mechanisms. Br J Pharmacol. https://doi.org/10.1111/bph.13649.
45. Pérez-Hernández Z-M, Villanueva-Porras D, Veja-Avila E, Chavarría A. 2016. A potential alternative against neurodegenerative diseases: Phytodrugs. Oxid Med Cell Longev 2016: 8378613. https://doi.org/10.1155/2016/8378613.
46. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL. 1992. Vitamin E atenuantes the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29: 699–701.
47. Pinto NV, Alexandre BS, Neves KRT, Silva AH, Leal LKAM, Viana GSB. 2015. Neuroprotective properties of the standardized extract from Camellia sinensis (green tea) and its main bioactive components, epicatechin and epigallocatechin gallate, in the 6-OHDA model of Parkinson's disease. Evid Based Complement Alternat Med 2015: 161092. https://doi.org/10.1155/2015/161092.
48. RajaSankar S, Manivasagam T, Sankar V, et al. 2009. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. J Ethnopharmacol 125: 369–373.
49. Ramírez-Moreno JM, Salguero Bodes I, Romaskevych O, Duran-Herrera MC. 2015. Broad bean (Vicia faba) consumption and Parkinson's disease: a natural source of L-dopa to consider. Neurologia 30: 375–376. https://doi.org/10.1016/j.nrl.2013.08.006.
50. Rabey JM, Vered Y, Shabtai H, Graff E, Korczyn AD. 1992. Improvement of Parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 55: 725–727.
51. Ray SN, Yadav SK, Singh D, Singh SP. 2016. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. J Chem Neuroanat 71: 41–49.
52. Roghani M, Niknam A, Jalale- Nadoushan MR, Khalili M, Baluchnejadmojarad T. 2010. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat modelo of hemi-Parkinsonism. Brain Res Bull 82: 279–283.
53. Sankar RS, Manivasagam T, Surendran S. 2009. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neurosci Lett 454: 11–15.
54. Schmidt N, Ferger B. 2001. Neurochemical findings in the MPTP model Parkinson's disease. J Neural Transm 108: 1263–1282.
55. Shalavadi MH, Chandrashekhar VM, Avinash SP, Sowmya C, Ramkishan A. 2012. Neuroprotectie activity of Stereospermum suaveleons DC against 6-OHDA induced Parkinson's disease model. Indian J Pharm 44: 737–743.
56. Smeriglio A, Barreca D, Bellocco E, Trombetta D. 2016a. Proanthocyanidins and hydrolysable tannins: occurrence, dietary intake and pharmacological effects. Br J Pharmacol. https://doi.org/10.1111/bph.13630.
57. Smeriglio A, Barreca D, Bellocco E, Trombetta D. 2016b. Chemistry pharmacology and health benefits of anthocyanins. Phytother Res 30: 1265–1286.
58. Smulder K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. 2016. Pharmacological treatment in Parkinson's disease: effects on gait. Parkinsonism Relat Disord 31:3–13.
59. Sun A, Xu X, Lin J, Cui X, Xu R. 2015. Neuroprotection by saponins. Phytother Res 29: 187–200. https://doi.org/10.1002/ptr.5246.
60. Suliman NA, Mat Taib CN, Mohd Moklas MA, Adenan MI, Hidayat Baharuldin MT, Basir R. 2016. Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic. Evid Bases Complement Alternat Med 2016: 1–12. http://dx.doi.org/10.1155/2016/4391375.
61. Schepetkin IA, Ramstead AG, Kirpotina LN, Voyich JM, Jutila MA, Quinn MT. 2016. Therapeutic potential of polyphenols from Epilobium angustifolium (Fireweed). Phytother Res 30: 1287–1297.
62. Shen CY, Jiang JG, Yang L, Wang DW, Zhu W. 2016. Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery. Br J Pharmacol. https://doi.org/10.1111/bph.13631.
63. Stohs SJ, Badmaev V. 2016. A review of natural stimulant and non-stimulant thermogenic agents. Phytother Res 30: 732–740.
64. Tan EK, Tan C, Fook-Chong SM, et al. 2003. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 216: 163–167.
65. Tanaka K, Galduróz RF, Gobbi LT, Galduróz JC. 2013. Ginkgo biloba em um modelo animal da doença de Parkinson: uma revisão sistemática. Curr Neuropharmacol 11: 430–435. https://doi.org/102174/1570159X11311040006.
66. Toulouse A, Sullivan AM. 2008. Progress in Parkinson's disease – where do we stand? Prog Neurobiol 85: 376–392.
67. Wang YQ, Wang MY, Fu XR, et al. 2015. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron. Free Radic Res 49: 1069–1080. https://doi.org/10.3109/10715762.2015.1032958.
68. Xu CL, Qu R, Zhang J, Li LF, Ma SP. 2013. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats. Fitoterapia 90: 112–118.
69. Yadav SK, Prakash J, Chouhan S, et al. 2014. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int 65: 1–13.
70. Yang CS, Chen G, Wu Q. 2014. Recent scientific studies of a traditional Chinese medicine, tea, on prevention of chronic diseases. J Tradit Complement Med 4: 17–23. https://doi.org/10.4103/2225-4110.124326.
71. Yu RL, Tan CH, Wu RM. 2015. The impact of nocturnal disturbances on daily quality of life in patients with Parkinson's disease. Neuropsychiatr Dis Treat 11: 2005–2012.
72. Yu X, He GR, Sun L, et al. 2012. Assessment of the treatment effect of baicalein on a model Parkinsonian tremor and elucidation of the mechanism. Life Sci 91: 513.
73. Zhang F, Lu J, Zhang JG, Xie JX. 2015. Protective effects of a polysaccharide from spirulina platensis on dopaminergic neurons in an MPTP-induced Parkinson's disease model in C57BL/61 mice. Neural Regen Res 10: 308–313.
74. Zhang HN, An CN, Zhang HN, Pu XP. 2010. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. Neurosci Lett 474: 99–103.
75. +-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem 364: 209–216.
76. Zhao L, Pux XP. 2007. Neuroprotective effect of acteroside against MPTP-induced mouse modelo of Parkinson's disease. Chin Pharmacol Bull 23: 42–46.
77. Zhu G, Wang X, Chen Y, et al. 2010. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neuroprotexicity via inhibiting apoptosis and upregulating glial cell line derived neurothipic fator in a rat modelo of Parkinson's disease. Planta Med 76: 1820–1826.